Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Verona Pharma plc ( NASDAQ:VRNA ) is possibly approaching a major achievement in its business, so we would like ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Verona Pharma (NASDAQ:VRNA – Get Free Report) had its price target raised by investment analysts at Wells Fargo & Company ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

Sanctuary Advisors LLC acquired a new stake in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) in the third quarter, ...

European equities traded in the US as American depositary receipts were trending higher late Tuesday morning, rising 0.34% to 1,316.18 on the S&P Europe Select ADR Index. From continental Europe, the ...

GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...